Interview with Catherine Bourrienne-Bautista, Managing Director, GEMME
Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap…
As dermo-cosmetics inventors, Pierre Fabre Dermo Cosmetics innovates in skin care and hair care fields and solutions following a sacrosanct principle of beauty rooted in ethics.
Backed by a pharmaceutical laboratory, the key to our scientific excellence, Pierre Fabre designs dermo-cosmetic treatments according to the most rigorous criteria for efficacy and safety. At Pierre Farbe, we are focused on acquiring the most cutting-edge expertise and technology, particularly in natural substances, hydrotherapy in dermatology, biotechnologies, and sterile cosmetics.
Recommended by health care professionals, our dermo-cosmetic treatments are administered by staff trained in our beauty ethics approach, thus guaranteeing individually tailored solutions.
As specialists in dermatological therapy with Pierre Fabre Dermatology we are no. 1 in Europe and no. 2 globally on the dermo-cosmetics market, with sales of over €1 billion across 130 countries, and a portfolio of 10 complementary brands.
Pierre Fabre is committed to developing our brands in all parts of the world. Each brand in our portfolio has its own DNA and is positioned to target a different type skin types and needs. Our brands are based on natural active ingredients: thermal spring water for Avène, Rhealba® Oat for A-Derma, plant extracts for Klorane and Elancyl, essential oils and plant extracts for René Furterer. Our dermo-cosmetics products are developed, clinically tested and manufactured according to the standards set out by the pharmaceutical industry.
Contact
Pierre Fabre Dermo-Cosmetics
Les Cauquillous
81506 Lavaur Cedex
+33 149 10 81 68
Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap…
Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes in the French pharmaceutical market and to what extent has France kept up?…
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
FEFIS represents 11 different associations across the industry with a very broad scope. How does the organization represent all of these different sectors? FEFIS represents as much as possible activities…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
